Clinical research of Yiqi Sanju Formula in treating central obese men at high risk of metabolic syndrome

Journal of Chinese Integrative Medicine

Volumn 5, Issue 3, 2007, Pages 263-267

  He, Chun Yan ^a   Wang, Wen Jian ^a   Li, Bin ^b   Xu, De Sheng ^a   Chen, Wei Hua ^a   Ying, Jiang ^a   He, Yan Ming ^a  

^a FUDAN UNIVERSITY   (China)

^b Fengcheng Hospital   (China)

Author keywords

Insulin; Metabolic syndrome; Obesity; Traditional Chinese medicine

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; FATTY ACID; HERBACEOUS AGENT; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; YIQI SANJU FORMULA;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FIBRINOLYSIS; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; TREATMENT DURATION; VOLUNTEER; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 34249745629     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20070307     Document Type: Article

References (15)

1. Gu DF, Reynolds K, Yang WJ, et al. The prevalence of metabolic syndrome in the general adult population aged 35-74 years in China. Zhongguo Tang Niao Bing Za Zhi. 2005; 13(3): 181-185. Chinese with abstract in English.
2. Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism. 2002; 51(6): 743-749.
3. Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract. 2006; 71(1): 92-100.
4. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006; 17(1): 4-12.
5. Mertens I, Ballaux D, Funahashi T, et al. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inlammation. Thromb Haemost. 2005; 94(6): 1190-1195.
6. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006; 26(10): 2200-2207.
7. Wang WJ. Foundation and application of aggregation theory in traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao. 2007; 5 (2): 111-114. Chinese with abstract in English.
8. Wang SH, Wang WJ, Wang XF, et al. Effect of astragalus polysaccharides and berberine on carbohydrate metabolism and cell differentiation in 3T3-L1 adipocytes. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004; 24 (10): 926-928. Chinese with abstract in English.
9. He YM, Wang WJ, Chen WH, et al. Effects of Pollen Typhae total flavone on glucose and lipid metabolism in 3T3-L1 adipocytes. Zhong Xi Yi Jie He Xue Bao. 2006; 4(6): 593-595. Chinese with abstract in English.
10. Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract. 2006; 71 (1): 92-100.
11. Kahn SE, Zinman B, Haffner SM, et al. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes. 2006; 55(8): 2357-2364.
12. Bo S, Gambino R, Uberti B, et al. Does C-reactive protein identify a subclinical metabolic disease in healthy subjects? Eur J Clin Invest. 2005, 35(4): 265-270.
13. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep. 2006; 6(3): 177-181.
14. Nieuwdorp M, Stroes ES, Meijers JC, et al. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol. 2005; 5(2): 155-159.
15. Umpaichitra V, Hussain MM, Castells S. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity. Pediatr Res. 2005; 58(3): 483-487.